A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)
A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age
Sponsor: Merck Sharp & Dohme LLC
A PHASE3 clinical study on Pneumococcal Disease, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 13 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Oct 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2024 — Jun 2024 [monthly]
Completed PHASE3
-
Jul 2023 — Apr 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Oct 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
Sep 2022 — Oct 2022 [monthly]
Recruiting PHASE3
First recorded
Aug 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .